This NMT Workstream was formed in 2021 to expand the PVRI community’s awareness and understanding of emerging device technologies for treating and diagnosing PH and RHF. It comprises experienced colleagues from academia, pharma, and regulatory fields, each with expertise in drug, device, and combination development.
Members aim to innovate and change current thinking, working in sub-groups:
'Inhalation Therapies' led by Sylvia Nikkho and Sandeep Sahay
'Therapeutic Device Technologies' led by Marc Pritzker and John Scandurra
'New Therapies' led by Sudarshan Rajagopal
'Imaging Technologies' led by Rahaghi Farbod, Ben Lavon and Alex Dusek
'Artificial Intelligence' led by Hilary DuBrock, Rahaghi Farbod and Nick Villabos
'Metabolic and Microbiome' led by Thenappan Thenappan
The group meets on the first Friday of each month at 15:00 BST/GMT. If you’re interested in joining this Workstream, please get in touch.
Our Regional Task Forces don't yet have global coverage. If you're interested in starting one, please contact us.
2025–26 IDDI Workstream & Task Forces Report
PVRI’s latest report highlights how global IDDI Workstreams and Task Forces are accelerating progress in pulmonary hypertension research, care, and innovation. Discover key achievements from across regions and specialties.
Interested in accessing global data on PH patient experience? Almost 4,000 patients and carers across 85 countries completed our PH Global Patient Survey (PHGPS). The data covers all PH groups and every stage of the patient journey — from diagnostic tests and timelines to treatments, genetic testing, financial pressures, hospital visits, research participation, quality of life, telemedicine, PROMs, and self-monitoring through digital tools.
The findings have the potential to improve patient care, guide future research and help us address unmet needs.
